Core One Labs (COOL) has appointed Dr. Santiago Ferro, Chief Executive Officer of Akome Biotech Ltd. as Chief Medical Officer.
Dr. Ferro will lead Core One Labs through clinical trials and commercialization of its psychedelic products.
Dr. Ferro is a graduate of Javeriana University Medical School in his native Bogotá, Colombia, where he specialized in Internal Medicine. Dr. Ferro received his sub-specialty training in Infectious Diseases at the University of Toronto. Following completion of his medical and specialty training, Dr. Ferro returned to Bogotá and established a private practice in both Internal Medicine and Infectious Diseases, while at the same time held academic positions at different teaching hospitals.
Dr. Ferro is a world-renowned physician with over 20 years of experience in the pharmaceuticals, biologicals and biotech industries. Throughout his career, Dr. Ferro has held many prestigious senior research and development management positions.
Dr. Ferro’s list of appointments includes Chief of Internal Medicine at Central Military Hospital in Bogotá, President of the Colombian Infectious Disease Society, Clinical Team Leader for new vaccines at Sanofi Pasteur in Toronto, Infectious Disease Expert at Novartis Pharmaceuticals in New Jersey and Medical Director at PATH’s Malaria Vaccine Initiative in Bethesda, Maryland.
Dr. Ferro was also VP of Clinical Affairs at Fio Corporation, where he led the clinical research and field implementations of the Fionet system in multiple countries in Africa and Latin America. Dr. Ferro also has an esteemed reputation in his fields of study, and has presented in multiple international scientific conferences, and has over twenty-five scientific publications in peer-reviewed journals and medical textbooks.
“I would like to welcome Dr. Ferro to the Core One team. Dr. Ferro’s breadth of experience in leading teams through product development, clinical and regulatory environments with major pharmaceutical companies, such as Sanofi Pasteur, Novartis and Glaxo Smith Klein are an invaluable asset to our team. We look forward to his leadership as we work towards the commercialization of psychedelic medicines,” stated Joel Shacker CEO of Core One Labs.
Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy.
Core One Labs Inc. (COOL) opened trading at C$0.65 per share.